Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896921 · ClinicalTrials.gov registry record · Phase 3
Switch to Maraviroc + Integrase Inhibitor
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01896921: Completed Phase 3 study, sponsored by University of Maryland, Baltimore.
NCT01896921 is a Phase 3 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01896921, a Phase 3 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
This clinical study proposes to evaluate the combination of maraviroc with an integrase strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced patients to document the efficacy, safety, and tolerability of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART regimen which lessens the risk of metabolic complications could improve long-term adherence and reduce the risk of certain co-morbidities associated with long-term ART use. If this new combination is found to be as efficacious as the standard regimen with enhanced tolerability and improved metabolic effects, there is great potential for altering the current practice of HIV medicine.
Primary Outcome
Number of patients virologically suppressed (HIV RNA \<50 copies/ml) at 48 weeks.
Interventions
- DRUG Switch to Maraviroc + Raltegravir or Dolutegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-12 |
| Phase | Phase 3 |
What the finished NCT01896921 record still lists
NCT01896921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Switch to Maraviroc + Raltegravir or Dolutegravir is the first listed.
NCT01896921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01896921 about?
NCT01896921 is a clinical study titled "Switch to Maraviroc + Integrase Inhibitor". This clinical study proposes to evaluate the combination of maraviroc with an integrase strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced patients to document the efficacy, safety, and tolerability of this combination in order to provide clinicians with a t...
What is the current status of trial NCT01896921?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2013-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01896921?
The interventions under investigation include: Switch to Maraviroc + Raltegravir or Dolutegravir (DRUG).
Who is sponsoring clinical trial NCT01896921?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01896921's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia